Search

Your search keyword '"Cassanello, Giulio"' showing total 24 results
Start Over Author "Cassanello, Giulio"
24 results on '"Cassanello, Giulio"'

1. CNS bridging radiotherapy achieves rapid cytoreduction before CAR T-cell therapy for aggressive B-cell lymphomas

Author

Cederquist, Gustav Y., Schefflein, Javin, Devlin, Sean M., Shah, Gunjan L., Shouval, Roni, Hubbeling, Harper, Tringale, Kathryn, Alarcon Tomas, Ana, Fregonese, Beatrice, Hajj, Carla, Boardman, Alexander, Luna De Abia, Alejandro, Corona, Magdalena, Cassanello, Giulio, Dahi, Parastoo B., Lin, Richard J., Ghione, Paola, Salles, Gilles, Perales, Miguel-Angel, Palomba, M. Lia, Falchi, Lorenzo, Scordo, Michael, Grommes, Christian, Yahalom, Joachim, and Imber, Brandon S.

Published
2024
Full Text
View/download PDF

2. Subsequent Malignancies After CD19-Targeted Chimeric Antigen Receptor T Cells in Patients With Lymphoma

Author

Lorenc, Rachel, Shouval, Roni, Flynn, Jessica R., Devlin, Sean M., Saldia, Amethyst, De Abia, Alejandro Luna, De Lapuerta, Magdalena Corona, Tomas, Ana Alarcon, Cassanello, Giulio, Leslie, Lori A., Rejeski, Kai, Lin, Richard J., Scordo, Michael, Shah, Gunjan L., Palomba, M. Lia, Salles, Gilles, Park, Jae, Giralt, Sergio A., Perales, Miguel-Angel, Ip, Andrew, and Dahi, Parastoo B.

Published
2024
Full Text
View/download PDF

4. Cancer cachexia and weight loss before CAR T-cell therapy for lymphoma are independently associated with poor outcomes

Author

Valtis, Yannis, Devlin, Sean, Shouval, Roni, Rejeski, Kai, Corona, Magdalena, Luna De Abia, Alejandro, Rivas-Delgado, Alfredo, Luttwak, Efrat, Cassanello, Giulio, Landego, Ivan, Schoder, Heiko, Bedmutha, Akshay, Boardman, Alexander, Shah, Gunjan L., Scordo, Michael, Perales, Miguel-Angel, Salles, Gilles, Palomba, Maria L., Shah, Urvi A., and Park, Jae H.

Published
2024
Full Text
View/download PDF

5. CNS Bridging Radiotherapy Achieves Rapid Cytoreduction Prior to CAR T Cell Therapy for Aggressive B-Cell Lymphoma

Author

Cederquist, Gustav, primary, Schefflein, Javin, additional, Devlin, Sean M., additional, Shah, Gunjan L, additional, Shouval, Roni, additional, Hubbeling, Harper, additional, Tringale, Kathryn R., additional, Alarcon Tomas, Ana, additional, Fregonese, Beatrice, additional, Hajj, Carla, additional, Boardman, Alexander P, additional, Luna De Abia, Alejandro, additional, Corona, Magdalena, additional, cassanello, Giulio, additional, Dahi, Parastoo B., additional, Lin, Richard J., additional, Ghione, Paola, additional, Salles, Gilles A., additional, Perales, Miguel-Angel, additional, Palomba, Maria Lia, additional, Falchi, Lorenzo, additional, Scordo, Michael, additional, Grommes, Christian, additional, Yahalom, Joachim, additional, and Imber, Brandon S., additional

Published
2024
Full Text
View/download PDF

6. Chimeric antigen receptor T‐cell therapy in secondary central nervous system lymphoma: A multicenter analysis.

Author

Alsouqi, Aseel, Ahmed, Gulrayz, Wang, Juntian, Cassanello, Giulio, Szabo, Aniko, Rojek, Alexandra E., Riedell, Peter A., Awan, Farrukh, Samples, Laura, Shadman, Mazyar, Hu, Marie, Bachanova, Veronika, Wesson, William, Ahmed, Nausheen, Iqbal, Madiha, Kharfan‐Dabaja, Mohamed A., Scordo, Michael, Johnson, P. Connor, Chen, Yi‐Bin, and Ito, Sawa

Published
2024
Full Text
View/download PDF

8. Impact of Tocilizumab on CAR-T Cells Outcome and Toxicity: Results from a Large B Cell Lymphoma Cohort

Author

Cassanello, Giulio, primary, Devlin, Sean M., additional, Landego, Ivan, additional, de Abia, Alejandro Luna, additional, Corona, Magdalena, additional, Rivas-Delgado, Alfredo, additional, Luttwak, Efrat, additional, Parascondola, Allison, additional, Saldia, Amethyst, additional, Dahi, Parastoo B., additional, Lin, Dr. Richard J., additional, Palomba, M. Lia, additional, Park, Jae H., additional, Salles, Gilles, additional, Perales, Miguel-Angel, additional, Scordo, Michael, additional, Shouval, Roni, additional, and Shah, Gunjan, additional

Published
2024
Full Text
View/download PDF

9. Digital Droplet PCR Based Monitoring of CAR-T Cell Expansion in Lymphoma Patients: Impact on Treatment Outcome

Author

Cassanello, Giulio, primary, Borsu, Laetitia, additional, Arcila, Maria E., additional, Yao, JinJuan, additional, Momeni-Boroujeni, Amir, additional, Ewalt, Mark D, additional, Patel, Utsav, additional, Chan, Roger, additional, Gray, Brandon, additional, de Abia, Alejandro Luna, additional, Corona, Magdalena, additional, Luttwak, Efrat, additional, Rivas-Delgado, Alfredo, additional, Landego, Ivan, additional, Parascondola, Allison, additional, Saldia, Amethyst, additional, Flynn, Jessica, additional, Devlin, Sean M., additional, Dahi, Parastoo B., additional, Lin, Dr. Richard J., additional, Palomba, M. Lia, additional, Scordo, Michael, additional, Shouval, Roni, additional, Salles, Gilles, additional, Perales, Miguel-Angel, additional, and Shah, Gunjan, additional

Published
2024
Full Text
View/download PDF

11. Detection of CAR-T Cell Persistence with Digital Droplet PCR: Correlation of In Vivo Expansion with Clinical Outcomes in a Cohort of B-Cell Lymphoma Patients

Author

Cassanello, Giulio, primary, Borsu, Laetitia, additional, Arcila, Maria E., additional, Yao, Jinjuan, additional, Momeni Boroujeni, Amir, additional, Ewalt, Mark, additional, Patel, Utsav, additional, Chan, Roger, additional, Gray, Brandon, additional, Luna De Abia, Alejandro, additional, Corona, Magdalena, additional, Luttwak, Efrat, additional, Landego, Ivan, additional, Parascondola, Allison, additional, Saldia, Amethyst, additional, Palomba, Maria Lia, additional, Alarcon Tomas, Ana, additional, Flynn, Jessica R, additional, Devlin, Sean M., additional, Dahi, Parastoo B., additional, Lin, Richard J., additional, Scordo, Michael, additional, Shouval, Roni, additional, Salles, Gilles, additional, Perales, Miguel-Angel, additional, and Shah, Gunjan L., additional

Published
2023
Full Text
View/download PDF

12. P-191 - Allogeneic hematopoietic stem cell transplantation in patients with advanced mycosis fungoides and Sézary syndrome: 2023 update of the Milan experience

Author

Onida, Francesco, Cavallaro, Francesca, Violetti, Silvia Alberti, Goldaniga, Maria, Barbullushi, Kordelia, Galassi, Giulia, Serpenti, Fabio, Cecchi, Nicola, Bellani, Valentina, Cassanello, Giulio, Galli, Nicole, Versino, Francesco, Rampi, Nicolò, Bosi, Alessandro, Croci, Giorgio Alberto, Simontacchi, Gabriele, Berti, Emilio, and Saporiti, Giorgia

Published
2023
Full Text
View/download PDF

13. Deciphering Treatment Patterns in Non-Severe Aplastic Anemia: An International Observational Study

Author

Fattizzo, Bruno, primary, Gurnari, Carmelo, additional, Cassanello, Giulio, additional, Bortolotti, Marta, additional, Awada, Hussein, additional, Giammarco, Sabrina, additional, Consonni, Dario, additional, Sica, Simona, additional, Gandhi, Shreyans, additional, Trikha, Roochi, additional, Maciejewski, Jaroslaw P., additional, Kulasekararaj, Austin, additional, and Barcellini, Wilma, additional

Published
2022
Full Text
View/download PDF

14. Allogeneic Hematopoietic Cell Transplantation in Advanced Phase Mycosis Fungoides and Sézary Syndrome: A Retrospective Analysis of 57 Consecutive Patients

Author

Cavallaro, Francesca, primary, Versino, Francesco, additional, Serpenti, Fabio, additional, Iacobelli, Simona, additional, Alberti Violetti, Silvia, additional, Saporiti, Giorgia, additional, Goldaniga, Maria, additional, Galassi, Giulia, additional, Bagnoli, Filippo, additional, Rampi, Nicolo', additional, Barbullushi, Kordelia, additional, Bosi, Alessandro, additional, Cassanello, Giulio, additional, Simontacchi, Gabriele, additional, Schiavone, Concetta, additional, Baldini, Luca, additional, Berti, Emilio, additional, and Onida, Francesco, additional

Published
2022
Full Text
View/download PDF

17. Low-Risk Myelodysplastic Syndrome Revisited: Morphological, Autoimmune, and Molecular Features as Predictors of Outcome in a Single Center Experience

Author

Fattizzo, Bruno, primary, Levati, Giorgia Virginia, additional, Giannotta, Juri Alessandro, additional, Cassanello, Giulio, additional, Cro, Lilla Marcella, additional, Zaninoni, Anna, additional, Barbieri, Marzia, additional, Croci, Giorgio Alberto, additional, Revelli, Nicoletta, additional, and Barcellini, Wilma, additional

Published
2022
Full Text
View/download PDF

18. Patterns and Safety of Glucocorticosteroids Use Following CD19 CAR-T Cell Therapy for B-Cell Lymphoma

Author

Luttwak, Efrat, Flynn, Jessica R., Devlin, Sean M., Cassanello, Giulio, Corona, Magdalena, Dahi, Parastoo B., Luna De Abia, Alejandro, Fein, Joshua, Giralt, Sergio A., Landego, Ivan, Lin, Richard J., Palomba, Maria Lia, Parascondola, Allison, Park, Jae H., Saldia, Amethyst, Scordo, Michael, Alarcon Tomas, Ana, Shah, Gunjan L., Perales, Miguel-Angel, Salles, Gilles, and Shouval, Roni

Published
2023
Full Text
View/download PDF

19. Real-Life Experience with Lenalidomide Plus Anti-CD20 Antibodies for the Treatment of Patients (pts) with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)

Author

Cassanello, Giulio, Rivas-Delgado, Alfredo, Luna De Abia, Alejandro, Corona, Magdalena, Luttwak, Efrat, Okwali, Michelle, Isgor, Irem, Galera, Pallavi, Boardman, Alexander P., Caron, Philip, David, Kevin A., Epstein-Peterson, Zachary D., Ghione, Paola, Hamlin, Paul A., Lue, Jennifer Kimberly, Horwitz, Steven M., Intlekofer, Andrew M., Johnson, William, Kumar, Anita, Moskowitz, Alison, Noy, Ariela, Owens, Colette, Palomba, Maria Lia, Stuver, Robert, Torka, Pallawi, Vardhana, Santosha A, Zelenetz, Andrew D., Salles, Gilles, and Falchi, Lorenzo

Published
2023
Full Text
View/download PDF

21. SARS-CoV-2 Interstitial Pneumonia Treated With Tocilizumab in a Patient Affected by Classical Hodgkin Lymphoma

Author

Rusconi, Chiara, primary, Cassanello, Giulio, additional, Guidetti, Anna, additional, Oltolini, Chiara, additional, Marasco, Vincenzo, additional, Morabito, Lucio, additional, Della Porta, Matteo, additional, Lanocita, Rodolfo, additional, Papagni, Gabriele, additional, Carniti, Cristiana, additional, and Corradini, Paolo, additional

Published
2020
Full Text
View/download PDF

22. Rituximab and lenalidomide for the treatment of relapsed or refractory indolent non-Hodgkin lymphoma: real-life experience.

Author

Cassanello G, Drill E, Rivas-Delgado A, Okwali M, Isgor I, Caron PC, Epstein-Peterson Z, Ghione P, Hamlin P, Lue J, Horwitz SM, Intlekofer AM, Johnson W, Kumar A, Moskowitz A, Noy A, Owens C, Palomba LM, Torka P, Galera P, Zelenetz AD, Salles G, and Falchi L

Abstract

The combination of rituximab and lenalidomide (R-len) stands as an established treatment for relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL). However, the reproducibility of clinical trial results in routine clinical practice is unknown. To address this gap in knowledge, we reviewed our experience with patients diagnosed with R/R follicular lymphoma (FL) or marginal zone lymphoma (MZL) treated with this combination. Eighty-four patients underwent treatment with R-len, 69 (82%) affected by FL and 15 (18%) by MZL. The median age at the time of treatment initiation was 65 years (range, 39-94), 38 patients (45%) had a pre-treatment FLIPI score of 3-5, 19 (23%) had a bulky disease, 29 (37%) had a lymphoma refractory to the last treatment line, while in 20 (24%) cases the disease was refractory to rituximab. The best overall response rate (ORR) was 82%, and 52% achieved a complete response (CR). The best CR rates for FL and MZL patients were 55% and 40%, respectively. With a median follow-up of 22 months, the median progression-free survival (mPFS) was 22 months (95% CI 19-36) and the 2-year overall survival (OS) was 83% (95% CI 74-93). The median duration of CR (DoCR) was 46 months (95% CI 22-NR). Factors associated with shorter PFS in multivariate analysis were bulky disease and rituximab refractoriness. The most common adverse events (AE) included hematologic toxicity, fatigue and gastrointestinal disorders, such as diarrhea and constipation. Neutropenia and thrombocytopenia were the most common severe toxicities (grade ≥3 in 25% and 4%, respectively). No new safety signals were reported. Real-life results of R-len in patients with R/R iNHL appear consistent with those reported in prospective studies, and further support its use as comparator arm in controlled clinical trials.

Published
2024
Full Text
View/download PDF

24. Use of steroids in the management of low-risk myelodysplastic syndromes with autoimmune features.

Author

Fattizzo B, Serpenti F, Versino F, Cassanello G, Cro LM, Barbieri M, Croci GA, Revelli N, Della Porta MG, and Barcellini W

Subjects
Humans, Aged, Prednisone therapeutic use, Retrospective Studies, Autoantibodies, Myelodysplastic Syndromes, Anemia, Hemolytic, Autoimmune drug therapy
Abstract

Background: The boundaries between myelodysplastic syndromes (MDS) and immune-mediated cytopenias are often difficult to establish and both conditions may benefit from immunosuppressive therapy. The optimal timing and doses of immunosuppressants are largely unknown., Materials and Methods: We systematically evaluated a retrospective cohort of 79 patients with low-risk MDS tested for anti-erythrocyte or anti-platelet autoantibodies to assess their frequency and the efficacy of immunosuppression, particularly with steroids., Results: We found autoantibody positivity in 43% of cases and overt autoimmune diseases in 18%, including autoimmune hemolytic anemia, immune thromboctyopenia, and Evans syndrome. Steroid treatment improved cytopenia in about half of patients, with 26% achieving a complete recovery lasting for a median of 12 months. Better responses were observed in anemic patients with anti-erythrocyte autoantibodies than in those with anti-platelet autoantibodies, and the combination with recombinant erythropoietin (7/10) had a possible synergistic effect. Steroid doses were heterogeneous depending on the clinical intent (i.e., anti-inflammatory, immunosuppressive, anabolizing). Patients treated with a dose of 1 mg/kg day of prednisone for overt autoimmune cytopenia showed high rates of complete responses (60%)., Discussion: This observation suggests a trial with a short course (2-3 weeks) of standard steroid doses to ascertain efficacy and properly silence the autoimmune pathogenic mechanism. Steroid-related adverse events (16% of cases) should be monitored carefully in this elderly, frail population. In conclusion, features of autoimmunity are present in more than two-thirds of low-risk MDS patients and a trial with prednisone 0.5-1 mg/kg day for 2-3 weeks, with proper monitoring of adverse events, may be useful to improve cytopenias in selected cases.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results